Research & Development Agrmnt

Proteome Sciences PLC
3 April 2001



                                  PRESS RELEASE

                                            3 April 2001

    PROTEOME SCIENCES ASSOCIATE, INTRONN, ANNOUNCES HPV AND CERVICAL CANCER R&
    D AGREEMENT WITH NATIONAL CANCER INSTITUTE USING INTRONN'S SMARTTM
    TECHNOLOGY.

    Proteome Sciences plc, the AIM listed proteomics and gene expression
    research company, is pleased to announce that its US associate, Intronn
    LLC, has signed a cooperative research and development agreement (CRADA)
    with the laboratory of Dr. Carl Baker of the National Cancer Institute
    (NCI) within the National Institutes of Health in the USA.

    The agreement will involve Intronn and Dr. Baker combining their expertise
    and experience to develop an RNA based treatment for human papillomavirus
    infection (HPV) and cervical cancers induced by HPV infection. Dr. Baker's
    laboratory and Intronn will use Intronn's patented spliceosome mediated
    mRNA trans-splicing (SMaRTTM) technology to create highly specific
    treatments for human HPV infections and HPV-induced cervical cancers. Most
    cervical cancers are correlated with HPV infection.


    Commenting on this news Christopher Pearce, Chief Executive of Proteome
    Sciences said:-


        'Having the NCI, one of the world's most advanced cancer research
        centres, choose to work in collaboration with Intronn using its SMaRT
        platform is a recognition of the tremendous potential that this
        trans-splicing technology has as a therapeutic treatment for oncology
        based conditions'.


    Intronn has developed its proprietary SMaRTTM technology which has
    specific applications in genomics, gene knockdown and exon swapping that
    can be used in the human therapeutics and agriculture markets.


                                       ENDS

    For additional information contact:

    Proteome Sciences

    Christopher Pearce,

    Chief Executive Tel: [phone]


    Gerard J. McGarrity, Ph.D.

CEO, Intronn LLC Tel: [phone]

Public Relations

Ikon Associates

Adrian Shaw                Tel: [phone]

                          Mobile: [phone]

                          E-mail: [e-mail]